Trial shows that the antibiotic azithromycin does not prevent mild COVID-19 cases progressing to hospitalization or death
2021-07-10
(Press-News.org) A new study (the ATOMIC2 trial), presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and published simultaneously in The Lancet Respiratory Medicine, shows the antimicrobial drug azithromycin - already approved for use in multiple infections - does not prevent mild COVID-19 cases progressing to hospitalisation or death.
The study, by Dr Timothy Hinks, John Radcliffe Hospital and University of Oxford, UK, and colleagues, shows that azithromycin should not be used as a treatment for COVID-19 and all countries must stop using it for this purpose, to prevent resistance developing to azithromycin in other infections.
The SARS-CoV-2 pandemic has not only started a rush to develop new treatments, but also investigations of already approved drugs to determine if they too can be used to treat COVID-19. Azithromycin is an antibiotic used to treat serious chest infections including pneumonias and drug-resistant tuberculosis, trachoma - a common preventable cause of blindness - sinus infections, Lyme disease, skin infections and some sexually transmitted infections such as chlamydia.
The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggested it could have therapeutic potential against COVID-19. However, there is a lack of data from randomised controlled trials of azithromycin to treat mild-to-moderate COVID-19 disease. In this study, the authors assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-to-moderate COVID-19. These were people with COVID-19 symptoms sufficiently severe to prompt them to seek hospital assessment, but not severe enough, initially, to require admission for oxygen therapy.
This randomised clinical trial at 19 centres in the UK enrolled adults aged 18 years and older, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with less than 14 days of symptoms, considered suitable for initial hospital assessment then treatment and/or observation at home. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to observation at home only. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the following 28 days.
A total of 298 participants were enrolled from June 2020 to January 2021 and 292 were included in the final analysis. The authors found no difference between the azithromycin and control groups in the risk of COVID-19 progressing to hospitalisation or death.
They explain that, in contrast to other studies the high dose of azithromycin in this new study (500 mg daily) and long duration (14 days) was selected to ensure that the trial adequately assessed potential antiviral, antibacterial and anti-inflammatory benefits. COVID-19 is considered to have a distinct early "viraemic" phase with a high viral load and a late inflammatory phase in some individuals, and therefore assessment of antiviral activity needed to be early in the disease course prior to onset of severe disease.
At the same time, it was not known what doses might be required to produce an adequate anti-inflammatory effect and so it was necessary to give a high dose of long duration to ensure the anti-inflammatory effect was tested throughout the late stage of innate/ acute phase of inflammatory cytokine dysregulation (known as the cytokine storm, which overwhelms the immune system of affected individuals and is often fatal).
The authors say: "In this trial of people with clinically-diagnosed mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death, or of time to hospitalisation... this finding, taken together with clear negative results from other studies across the disease course from early, low risk patients, to severe hospitalised disease, provides strong confirmation that azithromycin is not effective in treating COVID-19. It is essential that clinicians worldwide stop using this medication as a treatment for COVID-19. We now know it is not effective against COVID-19 and we need urgently to protect against the very real threat of driving drug resistance to this precious class of antibiotics."
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-07-10
For interviews with the report authors, please contact Dr Waasila Jassat, National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa E) waasilaj@nicd.ac.za T) +27(0)82 927 4138
Alternative contact in the ECCMID Press Room: Tony Kirby T) + 44(0)7834 385827 E) tony@tonykirby.com or Rachael Davies T) +44(0)797 456 0784 E) rachaelvdavies@hotmail.co.uk
Notes to editors:
[1] Wave 1: (14721 deaths/59617625 SA population)*100,000 = 24.7 deaths per 100,000 people
Wave 2: (28682 deaths/59617625 SA population)*100,000 = 48.1 deaths per 100,000 ...
2021-07-10
New research presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) shows the importance of receiving the second dose of a COVID-19 vaccine and also the need to constantly review and update vaccines to deal with new variants of concern. The study is by Dr Nicole Schneiderhan-Marra, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany, and colleagues.
While vaccines have begun to bring the pandemic under control in certain countries, it remains unclear how effective these vaccines will continue to be as the virus mutates and evolves. The protection generated against the virus by vaccination is normally measured by antibodies, with a certain group ...
2021-07-10
A presentation at this year's European Congress on Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, will discuss the growing evidence that the beta SARS-CoV-2 variant first identified in South Africa is leading to more severe disease in people living with HIV, and that failure to clear SARS-CoV-2 infection in a patient with advanced HIV creates conditions that can lead to evolution of dangerous mutations in SARS-CoV-2.
Control of HIV with antiretroviral therapy could be the key to preventing such evolution of SARS-CoV-2 in patients with advanced HIV, since clearance of the virus is compromised if HIV is allowed to replicate for ...
2021-07-09
Nashville, Tenn. (4:14 p.m. EDT--July 9, 2021)--Orthopedic surgeons know that knee surgeries that require revisions have inferior outcomes compared with primary surgeries but until now, the reason for this was unknown. Today a team of orthopedic physicians reports that opting for a transtibial surgical approach and choosing an inference screw for femoral and tibial fixation will improve the patient's odds of having a significantly better six-year clinical outcome.
The research was presented today at the American Orthopedic Society of Sports Medicine- Arthroscopy Association of North America Combined 2021 Annual Meeting by Rick Wright MD, ...
2021-07-09
Sea otters are the smallest marine mammal. As cold-water dwellers, staying warm is a top priority, but their dense fur only goes so far. We have long known that high metabolism generates the heat they need to survive, but we didn't know how they were producing the heat -- until now.
Researchers recently discovered that sea otters' muscles use enough energy through leak respiration, energy not used to perform tasks, that it accounts for their high metabolic rate. The finding explains how sea otters survive in cold water.
Physiologist Tray Wright, research assistant professor in Texas A&M University's College of Education & Human Development, conducted the study along with colleagues ...
2021-07-09
In the United States, nearly every pediatric doctor's visit begins with three measurements: weight, height and head circumference. Compared to average growth charts of children across the country, established in the 1970s, a child's numbers can confirm typical development or provide a diagnostic baseline to assess deviations from the curve. Yet, the brain, of vital importance to the child's development, is merely hinted at in these measurements.
Head circumference may indicate a head growth issue, which could be further investigated to determine if there is an issue with brain size or extra fluid. But now, in the age of ...
2021-07-09
Growth impairment, a common complication of Crohn's disease in children, occurs more often in males than females, but the reasons are unclear. Now, a physician-scientist from Weill Cornell Medicine and NewYork-Presbyterian and colleagues at eight other centers have found that factors associated with statural growth differ by sex. Their recent publication, identified as the "Editor's Choice / Leading Off" article and receiving a mention on the cover of the June issue of Inflammatory Bowel Diseases, underscores the need for investigating and developing sex-specific treatment strategies for children with Crohn's disease, an approach that is not currently part ...
2021-07-09
Nashville, Tenn., (3:40 EDT--July 9, 2021)--An analysis of MRI images of the tissue grafts used for patients who underwent surgery to repair the anterior cruciate knee ligament suggests grafts used from the quadriceps may be superior to tissue grafts from the hamstring. The research was presented today at the American Orthopaedic Society for Sports Medicine - Arthroscopy Association of North America Combined 2021 Annual Meeting.
Younger patients who required ACL reconstruction surgery have historically been treated with a hamstring graft to replace the injured ACL, but preliminary evidence suggests a graft from the quadriceps may be superior. Researchers from the Hospital for Special Surgery in New ...
2021-07-09
Why do some Europeans discriminate against Muslim immigrants, and how can these instances of prejudice be reduced? Political scientist Nicholas Sambanis has spent the last few years looking into this question by conducting innovative studies at train stations across Germany involving willing participants, unknowing bystanders and, most recently, bags of lemons.
His newest study, co-authored with Donghyun Danny Choi at the University of Pittsburgh and Mathias Poertner at Texas A&M University, was published July 8 in the American Journal of Political Science and finds evidence of significant discrimination against Muslim women during everyday interactions with native Germans. That evidence comes from experimental interventions set up on train platforms ...
2021-07-09
Plants have microscopically small pores on the surface of their leaves, the stomata. With their help, they regulate the influx of carbon dioxide for photosynthesis. They also use the stomata to prevent the loss of too much water and withering away during drought.
The stomatal pores are surrounded by two guard cells. If the internal pressure of these cells drops, they slacken and close the pore. If the pressure rises, the cells move apart and the pore widens.
The stomatal movements are thus regulated by the guard cells. Signalling pathways in these cells are so complex that it is difficult for humans to intervene with them directly. However, researchers of the Julius-Maximilians-Universität (JMU) Würzburg in ...
LAST 30 PRESS RELEASES:
[Press-News.org] Trial shows that the antibiotic azithromycin does not prevent mild COVID-19 cases progressing to hospitalization or death
